Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Drug: PARP inhibitor
- Registration Number
- NCT04724031
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Brief Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
- Detailed Description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
- women >18 years old with advanced high grade ovarian cancer
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description One cohort PARP inhibitor women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
- Primary Outcome Measures
Name Time Method Evaluation of Progression Free Survival 12/2022
- Secondary Outcome Measures
Name Time Method Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer 12/2021 Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer 12/2021
Trial Locations
- Locations (1)
Adamantia Nikolaidi
🇬🇷Athens, Attiki, Greece